Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2016
Summary
GlobalData's Medical Devices sector report, “Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2016" provides an overview of Vagus Nerve Stimulators currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Vagus Nerve Stimulators pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Vagus Nerve Stimulators under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Vagus Nerve Stimulators and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Vagus Nerve Stimulators under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table Of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Introduction 7
2.1 Vagus Nerve Stimulators Overview 7
3 Products under Development 8
3.1 Vagus Nerve Stimulators - Pipeline Products by Stage of Development 8
3.2 Vagus Nerve Stimulators - Pipeline Products by Territory 9
3.3 Vagus Nerve Stimulators - Pipeline Products by Regulatory Path 10
3.4 Vagus Nerve Stimulators - Pipeline Products by Estimated Approval Date 11
3.5 Vagus Nerve Stimulators - Ongoing Clinical Trials 12
4 Vagus Nerve Stimulators - Pipeline Products under Development by Companies 13
4.1 Vagus Nerve Stimulators Companies - Pipeline Products by Stage of Development 13
4.2 Vagus Nerve Stimulators - Pipeline Products by Stage of Development 14
5 Vagus Nerve Stimulators Companies and Product Overview 15
5.1 BioControl Medical Company Overview 15
5.1.1 BioControl Medical Pipeline Products & Ongoing Clinical Trials Overview 15
5.2 Boston Scientific Corporation Company Overview 17
5.2.1 Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 17
5.3 CerboMed GmbH Company Overview 21
5.3.1 CerboMed GmbH Pipeline Products & Ongoing Clinical Trials Overview 21
5.4 Cerebral RX Ltd. Company Overview 22
5.4.1 Cerebral RX Ltd. Pipeline Products & Ongoing Clinical Trials Overview 22
5.5 Cyberonics, Inc. Company Overview 23
5.5.1 Cyberonics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 23
5.6 DuoCure Ltd. Company Overview 27
5.6.1 DuoCure Ltd. Pipeline Products & Ongoing Clinical Trials Overview 27
5.7 ElectroCore, LLC Company Overview 28
5.7.1 ElectroCore, LLC Pipeline Products & Ongoing Clinical Trials Overview 28
5.8 LivaNova PLC Company Overview 34
5.8.1 LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 34
5.9 Medical University of South Carolina Company Overview 40
5.9.1 Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 40
5.10 MicroTransponder Inc. Company Overview 42
5.10.1 MicroTransponder Inc. Pipeline Products & Ongoing Clinical Trials Overview 42
5.11 Neurostream Technologies G.P. (Inactive) Company Overview 49
5.11.1 Neurostream Technologies G.P. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 49
5.12 Purdue University Company Overview 51
5.12.1 Purdue University Pipeline Products & Ongoing Clinical Trials Overview 51
5.13 Setpoint Medical Corp Company Overview 52
5.13.1 Setpoint Medical Corp Pipeline Products & Ongoing Clinical Trials Overview 52
5.14 Trifectas Medical Corp. Company Overview 56
5.14.1 Trifectas Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview 56
6 Vagus Nerve Stimulators- Recent Developments 57
6.1 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 57
6.2 Oct 19, 2016: SetPoint Medical Presents Positive Clinical Results in Crohn’s Disease 58
6.3 Oct 19, 2016: St. Jude Medical Reports Third Quarter 2016 Results 59
6.4 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 60
6.5 Sep 29, 2016: LivaNova Announces Half-Year Financial Report 61
6.6 Aug 03, 2016: LivaNova Reports Second Quarter 2016 Results 69
6.7 Aug 01, 2016: LivaNova Names Chief Operating Officer 70
6.8 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016 71
6.9 Jul 26, 2016: Use of electroCore’s therapy reduces frequency of migraine attacks in chronic patients 72
6.10 Jul 21, 2016: Reorganization of electroCore management team as Frank Amato becomes CEO and founder JP Errico becomes Chief Science and Strategy Officer 73
6.11 Jul 20, 2016: St. Jude Medical Reports Second Quarter 2016 Results 73
6.12 Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors 75
6.13 Jul 06, 2016: LivaNova Sets Operating Model and Supporting Organization 75
6.14 Jul 05, 2016: Breakthrough First-in-Human Study Shows Vagus Nerve Stimulation Significantly Reduces Rheumatoid Arthritis Symptoms, Inhibits Cytokine Production 76
6.15 Jun 29, 2016: ElectroCore Raises USD1.5 Million in Venture Financing 77
6.16 Jun 24, 2016: Five presentations at AHS meeting provide new insights into non-invasive vagus nerve stimulation’s mode of action 77
6.17 Jun 15, 2016: ElectroCore’s non-invasive vagus nerve stimulation (nVNS) demonstrates efficacy in preventing cluster headache and menstrual migraine 78
6.18 Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation 78
6.19 Jun 06, 2016: Seven presentations on electroCore’s treatment for cluster headache and migraine will feature at American Headache Society science meeting 79
6.20 May 31, 2016: Ergoresearch announce the nomination of an Executive Vice-President 80
6.21 May 27, 2016: Ergoresearch Reports its Results for the Quarter Ended March 31, 2016 81
6.22 May 17, 2016: GammaCore is both effective and cost effective for the treatment of cluster headache 81
6.23 May 04, 2016: LivaNova Reports First Quarter 2016 Results 82
6.24 Apr 19, 2016: Studies presented at the American Academy of Neurology meeting confirm nVNS is stimulating the vagus nerve non-invasively and that nVNS can be effective in preventing menstrual migraine 83
6.25 Apr 01, 2016: NICE provides positive guidance on electroCore’s gammaCore treatment for the prevention and acute treatment of migraine and cluster headache 84
6.26 Feb 29, 2016: Second Quarter Results ended December 31, 2015 - Ergoresearch reports its results for the quarter ended December 31, 2015 85
6.27 Feb 24, 2016: LivaNova Reports 2015 Annual and Fourth Quarter Financial Results 85
6.28 Jan 19, 2016: University of Bonn study shows that non-invasive vagus nerve stimulation (nVNS) device reduces number of migraine attacks and their intensity 88
6.29 Jan 06, 2016: ElectroCore Appoints Desitin to Launch gammaCore for the Treatment of Primary Headache across Germany 89
6.30 Jan 05, 2016: LivaNova Provides Update on FDA Warning Letter 89
6.31 Dec 23, 2015: Mittel Plans to Sell 6% Interest in LivaNova 90
6.32 Nov 19, 2015: Checkpoint Surgical Raises USD7.5 Million in Venture Financing 90
6.33 Nov 12, 2015: LivaNova Provides Business Update 90
7 Appendix 93
7.1 Methodology 93
7.2 About GlobalData 95
7.3 Contact Us 95
7.4 Disclaimer 96
List Of Tables
1.1 List of Tables
Table 1: Vagus Nerve Stimulators - Pipeline Products by Stage of Development 8
Table 2: Vagus Nerve Stimulators - Pipeline Products by Territory 9
Table 3: Vagus Nerve Stimulators - Pipeline Products by Regulatory Path 10
Table 4: Vagus Nerve Stimulators - Pipeline Products by Estimated Approval Date 11
Table 5: Vagus Nerve Stimulators - Ongoing Clinical Trials 12
Table 6: Vagus Nerve Stimulators Companies - Pipeline Products by Stage of Development 13
Table 7: Vagus Nerve Stimulators - Pipeline Products by Stage of Development 14
Table 8: BioControl Medical Pipeline Products & Ongoing Clinical Trials Overview 15
Table 9: CardioFit System - Product Status 15
Table 10: CardioFit System - Product Description 16
Table 11: Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 17
Table 12: AMT System - Product Status 17
Table 13: AMT System - Product Description 18
Table 14: Vagal Nerve Stimulator - Product Status 18
Table 15: Vagal Nerve Stimulator - Product Description 18
Table 16: Boston Scientific Corporation - Ongoing Clinical Trials Overview 19
Table 17: Vagal Nerve Stimulator - Neural Cardiac Therapy for Heart Failure Study 20
Table 18: CerboMed GmbH Pipeline Products & Ongoing Clinical Trials Overview 21
Table 19: t-VNS - Dementia - Product Status 21
Table 20: t-VNS - Dementia - Product Description 21
Table 21: Cerebral RX Ltd. Pipeline Products & Ongoing Clinical Trials Overview 22
Table 22: FitNes System - Alzheimer’s Disease - Product Status 22
Table 23: FitNes System - Alzheimer’s Disease - Product Description 22
Table 24: Cyberonics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 23
Table 25: Aspire NP - Product Status 23
Table 26: Aspire NP - Product Description 24
Table 27: Centro Generator - Product Status 24
Table 28: Centro Generator - Product Description 24
Table 29: Griffin - Pulse Generator - Product Status 25
Table 30: Griffin - Pulse Generator - Product Description 25
Table 31: Nerve Wrap - Product Status 25
Table 32: Nerve Wrap - Product Description 26
Table 33: PhoenixRF SR - Product Status 26
Table 34: PhoenixRF SR - Product Description 26
Table 35: DuoCure Ltd. Pipeline Products & Ongoing Clinical Trials Overview 27
Table 36: Intraluminal Implantable Device - Product Status 27
Table 37: Intraluminal Implantable Device - Product Description 27
Table 38: ElectroCore, LLC Pipeline Products & Ongoing Clinical Trials Overview 28
Table 39: GammaCore - Cluster Headache - Product Status 28
Table 40: GammaCore - Cluster Headache - Product Description 28
Table 41: GammaCore - Medication Overuse Headache - Product Status 29
Table 42: GammaCore - Medication Overuse Headache - Product Description 29
Table 43: GammaCore - Migraine - Product Status 30
Table 44: GammaCore - Migraine - Product Description 30
Table 45: ElectroCore, LLC - Ongoing Clinical Trials Overview 31
Table 46: GammaCore - Migraine - A Prospective, Multi-center, Randomized, Double-blind, Sham-controlled Study of the gammaCore-S Non-invasive Vagus Nerve Stimulation Device (NVNS), for the Acute Treatment of Migraine 32
Table 47: GammaCore - Cluster Headache - A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of the gammaCore, a Non-invasive Neurostimulator Device, for the Prevention of Episodic Migraine 33
Table 48: GammaCore - Cluster Headache - Non-Invasive Vagus Nerve Stimulation Treatment for Headache Using GammaCore 33
Table 49: LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 34
Table 50: CentroSR Generator - Product Status 34
Table 51: CentroSR Generator - Product Description 35
Table 52: Equilia - Product Status 35
Table 53: Equilia - Product Description 35
Table 54: VITARIA System - Chronic Heart Failure - Product Status 36
Table 55: VITARIA System - Chronic Heart Failure - Product Description 36
Table 56: LivaNova PLC - Ongoing Clinical Trials Overview 37
Table 57: VITARIA System - Chronic Heart Failure - VITARIA Registry Study 38
Table 58: Equilia - Vagal Nerve Stimulation: Safe-guarding Heart Failure Patients (VANGUARD) 39
Table 59: Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 40
Table 60: Transcutaneous Auricular Vagus Nerve Stimulator (taVNS) - Product Status 40
Table 61: Transcutaneous Auricular Vagus Nerve Stimulator (taVNS) - Product Description 41
Table 62: MicroTransponder Inc. Pipeline Products & Ongoing Clinical Trials Overview 42
Table 63: SAINT System - Anxiety Disorders - Product Status 42
Table 64: SAINT System - Anxiety Disorders - Product Description 43
Table 65: SAINT System - Tinnitus - Product Status 43
Table 66: SAINT System - Tinnitus - Product Description 44
Table 67: Serenity System - Tinnitus - Product Status 45
Table 68: Serenity System - Tinnitus - Product Description 45
Table 69: Vivistim Device - Product Status 45
Table 70: Vivistim Device - Product Description 46
Table 71: MicroTransponder Inc. - Ongoing Clinical Trials Overview 47
Table 72: Vivistim Device - A Randomized Pilot Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function after Stroke (MicroTransponder's Vivistim System) - Study MT-St-02 - Stroke 48
Table 73: Neurostream Technologies G.P. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 49
Table 74: Neuromodulation Device - Epilepsy - Product Status 49
Table 75: Neuromodulation Device - Epilepsy - Product Description 49
Table 76: Neuromodulation Device - Sleep Apnea - Product Status 50
Table 77: Neuromodulation Device - Sleep Apnea - Product Description 50
Table 78: Purdue University Pipeline Products & Ongoing Clinical Trials Overview 51
Table 79: Bionode Device - Product Status 51
Table 80: Bionode Device - Product Description 51
Table 81: Setpoint Medical Corp Pipeline Products & Ongoing Clinical Trials Overview 52
Table 82: Implantable Neurostimulation Device - Rheumatoid Arthritis - Product Status 52
Table 83: Implantable Neurostimulation Device - Rheumatoid Arthritis - Product Description 52
Table 84: SetPoint Immune System Regulator - Crohn’s Disease - Product Status 53
Table 85: SetPoint Immune System Regulator - Crohn’s Disease - Product Description 53
Table 86: Setpoint Medical Corp - Ongoing Clinical Trials Overview 54
Table 87: SetPoint Immune System Regulator - Crohn’s Disease - Study of the Safety and Efficacy of Neurostimulation of the Cholinergic Anti-inflammatory Pathway Using a Vagal Nerve Stimulation Device in Patients with Active Refractory Crohn's Disease 55
Table 88: Trifectas Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview 56
Table 89: Neurostimulation Device - Stroke Recovery - Product Status 56
Table 90: Neurostimulation Device - Stroke Recovery - Product Description 56
Table 91: Glossary 94
List Of Figures
1.2 List of Figures
Figure 1: Vagus Nerve Stimulators - Pipeline Products by Stage of Development 8
Figure 2: Vagus Nerve Stimulators - Pipeline Products by Territory 9
Figure 3: Vagus Nerve Stimulators - Pipeline Products by Regulatory Path 10
Figure 4: Vagus Nerve Stimulators - Pipeline Products by Estimated Approval Date 11
Figure 5: Vagus Nerve Stimulators - Ongoing Clinical Trials 12
